Literature DB >> 35831771

External validation and comparison of CHA2DS2-VASc-RAF and CHA2DS2-VASc-LAF scores for predicting left atrial thrombus and spontaneous echo contrast in patients with non-valvular atrial fibrillation.

Nan Zheng1,2, Jun Zhang3,4.   

Abstract

PURPOSE: CHA2DS2-VASc-RAF (R is renal dysfunction, and AF is atrial fibrillation type) and CHA2DS2-VASc-LAF (L is left atrial diameter, and AF is atrial fibrillation type) scores have been developed to estimate the risk of left atrial thrombus (LAT) and spontaneous echo contrast (SEC) in patients with non-valvular atrial fibrillation (NVAF). However, few external validations have been conducted to assess their accuracy. Thus, this study aimed to validate and compare the two modified scores for predicting LAT/SEC in patients with NVAF.
METHODS: This study included 399 patients with NVAF who underwent transesophageal echocardiography. Risk factors related to LAT/SEC were identified through logistic regression analysis, and predictive value and diagnostic efficiency were evaluated using receiver operating characteristic (ROC) curve.
RESULTS: Approximately 9.8% (39/399) of the patients with NVAF had LAT/SEC. Multivariate logistic regression analysis showed that history of stroke/transient ischemic attack, congestive heart failure, non-paroxysmal atrial fibrillation, lack of anticoagulation therapy, enlarged left atrial diameter, enlarged left ventricular end diastolic diameter, decreased left ventricular ejection fraction, decreased left atrial appendage emptying velocity, and decreased estimated glomerular filtration rate were independent risk factors for LAT/SEC. The CHA2DS2-VASc-LAF (area under the ROC curve [AUC] = 0.839) and CHA2DS2-VASc-RAF (AUC = 0.829) scores showed larger predictive values than the CHA2DS2-VASc (AUC = 0.737) and CHADS2 (AUC = 0.736) scores. The AUC of the CHA2DS2-VASc-RAF score was similar to that of the CHA2DS2-VASc-LAF score (Z = 0.432; P = 0.666).
CONCLUSION: This study validated that the CHA2DS2-VASc-RAF and CHA2DS2-VASc-LAF scores are useful prognostic scoring systems for predicting LAT/SEC in patients with NVAF.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Atrial fibrillation; Left atrial thrombus; Spontaneous echo contrast

Year:  2022        PMID: 35831771     DOI: 10.1007/s10840-022-01285-y

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.759


  30 in total

1.  Risk assessment and management of atrial fibrillation patients with left atrial thrombus.

Authors:  Kazuo Miyazawa; Gregory Y H Lip
Journal:  Pacing Clin Electrophysiol       Date:  2018-12-04       Impact factor: 1.976

2.  Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus.

Authors:  Agnieszka Kapłon-Cieślicka; Monika Budnik; Monika Gawałko; Michał Peller; Iwona Gorczyca; Anna Michalska; Aldona Babiarz; Aleksandra Bodys; Robert Uliński; Maciej Żochowski; Piotr Scisło; Janusz Kochanowski; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Heart       Date:  2019-04-30       Impact factor: 5.994

Review 3.  Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature.

Authors:  Matteo Nicola Dario Di Minno; Pasquale Ambrosino; Antonio Dello Russo; Michela Casella; Elena Tremoli; Claudio Tondo
Journal:  Thromb Haemost       Date:  2015-11-26       Impact factor: 5.249

4.  Temporal trends of atrial fibrillation and/or rheumatic heart disease-related ischemic stroke, and anticoagulant use in Chinese population: An 8-year study.

Authors:  Junfeng Liu; Yanan Wang; Wen Guo; Yajun Cheng; Shihong Zhang; Bo Wu; Ming Liu
Journal:  Int J Cardiol       Date:  2020-08-16       Impact factor: 4.164

5.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.

Authors:  Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins
Journal:  Eur Heart J       Date:  2021-02-01       Impact factor: 29.983

6.  Routine Transesophageal Echocardiography in Atrial Fibrillation Before Electrical Cardioversion to Detect Left Atrial Thrombosis and Echocontrast.

Authors:  Sebastian Feickert; Giuseppe D Ancona; Hüseyin Ince; Kristof Graf; Elias Kugel; Monica Murero; Erdal Safak
Journal:  J Atr Fibrillation       Date:  2020-10-31

7.  Myopericarditis and myositis in a patient with COVID-19: a case report.

Authors:  Asad Shabbir; Christian Fielder Camm; Andrew Elkington; Lindsey Tilling; James Stirrup; Antoni Chan; Sacha Bull
Journal:  Eur Heart J Case Rep       Date:  2020-10-30

8.  Associations of socioeconomic status indicators and migrant status with risk of a low vegetable and fruit consumption in children.

Authors:  Mirte Boelens; Hein Raat; Anne I Wijtzes; Gea M Schouten; Dafna A Windhorst; Wilma Jansen
Journal:  SSM Popul Health       Date:  2022-02-04

9.  Refinement of CHADS2 and CHA2DS2-VASc scores predict left atrial thrombus or spontaneous echo contrast in nonvalvular atrial fibrillation patients.

Authors:  Miaomiao Cao; Huihui Guo; Xiao Zhao; Xiyang Li; Chaofeng Sun
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

10.  Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge.

Authors:  Giuseppe Lippi; Fabian Sanchis-Gomar; Gianfranco Cervellin
Journal:  Int J Stroke       Date:  2020-01-19       Impact factor: 5.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.